Methadone induction in primary care (ANRS-Methaville): A phase III randomized intervention trial

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Roux, Perrine ^a,b,c   Michel, Laurent ^d,e,f   Cohen, Julien ^a,b,c   Mora, Marion ^a,b,c   Morel, Alain ^g   Aubertin, Jean Francois ^h   Desenclos, Jean Claude ⁱ   Spire, Bruno ^a,b,c   Carrieri, Patrizia M ^a,b,c  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f Centre Pierre Nicole   (France)

^g Oppelia   (France)

^h Institut de Veille Sanitaire ^*

ⁱ INSTITUT DE VEILLE SANITAIRE   (France)

Author keywords

Initiation; Methadone; Opioid maintenance treatment; Opioid use; Overdose; Primary care

Indexed keywords

METHADONE;

ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; FOLLOW UP; FRANCE; HUMAN; METHODOLOGY; MULTICENTER STUDY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; ORGANIZATION AND MANAGEMENT; PHASE 3 CLINICAL TRIAL; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

FOLLOW-UP STUDIES; FRANCE; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE; SUBSTANCE ABUSE TREATMENT CENTERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862764493     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-488     Document Type: Article

References (45)

1. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Mattick RP, Kimber J, Breen C, Davoli M, Cochrane Database Syst Rev 2008 2 D002207
2. A French prospective observational study of the treatment of chronic hepatitis C in drug abusers: a commentary. Michel L, Roux P, Cohen J, Carrieri MP, Gastroenterol Clin Biol 2009 33 1 Pt 1 15 16 author reply 16-17. 19084361
3. Buprenorphine use: the international experience. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE, Clin Infect Dis 2006 43 Suppl 4 197 S215 17109307 (Pubitemid 44901888)
4. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Emmanuelli J, Desenclos JC, Addiction 2005 100 11 1690 1700 10.1111/j.1360-0443.2005.01271.x 16277629 (Pubitemid 41626829)
5. Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France. Roux P, Villes V, Bry D, Spire B, Feroni I, Marcellin F, Carrieri MP, Addict Behav 2008 33 12 1625 1629 10.1016/j.addbeh.2008.07.018 18775604
6. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A, Drug Alcohol Depend 2003 69 2 175 181 10.1016/S0376-8716(02) 00312-5 12609698 (Pubitemid 36262027)
7. The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Gossop M, Marsden J, Stewart D, Kidd T, Addiction 2003 98 3 291 303 10.1046/j.1360-0443.2003.00296.x 12603229 (Pubitemid 36269568)
8. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). Hubbard RL, Craddock SG, Anderson J, J Subst Abuse Treat 2003 25 3 125 134 10.1016/S0740-5472(03)00130-2 14670518 (Pubitemid 37518373)
9. Methadone treatment practices and outcome for opiate addicts treated in drug clinics and in general practice: results from the National Treatment Outcome Research Study. Gossop M, Marsden J, Stewart D, Lehmann P, Strang J, Br J Gen Pract 1999 49 438 31 34 10622013 (Pubitemid 29027498)
10. Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for US policy. Weinrich M, Stuart M, JAMA 2000 283 10 1343 1348 10.1001/jama.283.10.1343 10714738 (Pubitemid 30129806)
11. Methadone maintenance in primary care: a randomized controlled trial. Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS, JAMA 2001 286 14 1724 1731 10.1001/jama.286.14.1724 11594897 (Pubitemid 33010258)
12. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. Strain EC, Bigelow GE, Liebson IA, Stitzer ML, JAMA 1999 281 11 1000 1005 10.1001/jama.281.11.1000 10086434 (Pubitemid 29143891)
13. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, Wood E, Drug Alcohol Depend 2007 87 1 39 45 10.1016/j.drugalcdep.2006.07.009 16959438 (Pubitemid 46074383)
14. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC, J Clin Psychiatry 1998 59 Suppl 20 22 33 quiz 34-57. 9881538 (Pubitemid 29001829)
15. The impact of benzodiazepine use on methadone maintenance treatment outcomes. Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S, J Addict Dis 2008 27 3 37 48 10.1080/10550880802122620 18956528
16. Leavitt SB, Methadone-Drug Interactions Forum: In Addiction Treatment 2005
17. Methadone: a new old drug with promises and pitfalls. Trafton JA, Ramani A, Curr Pain Headache Rep 2009 13 1 24 30 10.1007/s11916-009-0006-0 19126367
18. Chapter V. A comparison of CATI and non-CATI questionnaires. Groves RM, Mathiowetz NA, Vital and health statistics 1987 106 33 39
19. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Darke S, Hall W, Wodak A, Heather N, Ward J, Br J Addict 1992 87 5 733 742 10.1111/j.1360-0443.1992.tb02719.x 1591524
20. Psychometric properties of the Blood-borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ). Fry CL, Lintzeris N, Addiction 2003 98 2 171 178 10.1046/j.1360-0443.2003.00207.x 12534421 (Pubitemid 36140368)
21. Quantifying hepatitis C transmission risk using a new weighted scoring system for the Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ): applications for community-based HCV surveillance, education and prevention. Stoove MA, Fry CL, Lintzeris N, Harm Reduct J 2008 5 12 10.1186/1477-7517-5-12 18433470 (Pubitemid 351715998)
22. Prevalence of hepatitis C, B and D markers and histopathological aspects in a group of intravenous drug addicts. Lucidarme D, Foutrein P, Creusy C, Forzy G, Foutrein-Comes MC, Muyssen A, Bailly D, Parquet PJ, Filoche B, Gastroenterol Clin Biol 1994 18 11 964 968 7705584
23. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Lucidarme D, Bruandet A, Ilef D, Harbonnier J, Jacob C, Decoster A, Delamare C, Cyran C, Van Hoenacker AF, Fremaux D, et al. Epidemiol Infect 2004 132 4 699 708 10.1017/ S095026880400247X 15310172 (Pubitemid 39140102)
24. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale (in French). Fuhrer R, Rouillon F, Psychiatrie et Psychobiologie 1989 4 163 166 (Pubitemid 19210689)
25. Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Beck AT, Steer RA, Kovacs M, Garrison B, Am J Psychiatry 1985 142 5 559 563 3985195 (Pubitemid 15034623)
26. Further psychometric support for the Sensation Seeking Scale-Form V. Roberti JW, Storch EA, Bravata E, J Pers Assess 2003 81 3 291 292 10.1207/S15327752JPA8103-12 14638454 (Pubitemid 37541808)
27. Validity of the Fagerstrom test for nicotine dependence and of the Heaviness of Smoking Index among relatively light smokers. Etter JF, Duc TV, Perneger TV, Addiction 1999 94 2 269 281 10.1046/j.1360-0443.1999.94226910.x 10396794 (Pubitemid 29068967)
28. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M, Addiction 1993 88 6 791 804 10.1111/j.1360-0443.1993.tb02093.x 8329970 (Pubitemid 23194530)
29. Validation of the French version of the brief pain inventory in Canadian veterans suffering from traumatic stress. Poundja J, Fikretoglu D, Guay S, Brunet A, J Pain Symptom Manage 2007 33 6 720 726 10.1016/j.jpainsymman.2006.09. 031 17531912 (Pubitemid 46783993)
30. Patient-physician communication in the context of persistent pain: validation of a modified version of the patients' Perceived Involvement in Care Scale. Smith MY, Winkel G, Egert J, Diaz-Wionczek M, DuHamel KN, J Pain Symptom Manage 2006 32 1 71 81 10.1016/j.jpainsymman.2006.01.007 16824987 (Pubitemid 43974899)
31. The development of a Short Opiate Withdrawal Scale (SOWS). Gossop M, Addict Behav 1990 15 5 487 490 10.1016/0306-4603(90)90036-W 2248123 (Pubitemid 20333437)
32. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Ware J Jr, Kosinski M, Keller SD, Med Care 1996 34 3 220 233 10.1097/00005650-199603000-00003 8628042 (Pubitemid 126433231)
33. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, Howes MJ, Jin R, Secnik K, Spencer T, et al. Psychol Med 2005 35 2 245 256 10.1017/S0033291704002892 15841682 (Pubitemid 40259916)
34. In-patient treatment of opiate dependence: medium-term follow-up outcomes. Smyth BP, Barry J, Lane A, Cotter M, O'Neill M, Quinn C, Keenan E, Br J Psychiatry 2005 187 360 365 10.1192/bjp.187.4.360 16199796 (Pubitemid 41442389)
35. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. Maremmani I, Pani PP, Pacini M, Perugi G, J Subst Abuse Treat 2007 33 1 91 98 10.1016/j.jsat.2006.11.009 17588494 (Pubitemid 350198612)
36. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, Golz J, Kraus MR, Tretter F, Schafer M, Siegert J, et al. Drug Alcohol Depend 2008 95 3 245 257 10.1016/j.drugalcdep.2008.01.015 18337025
37. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. Carrieri MP, Leport C, Protopopescu C, Cassuto JP, Bouvet E, Peyramond D, Raffi F, Moatti JP, Chene G, Spire B, J Acquir Immune Defic Syndr 2006 41 4 477 485 10.1097/01.qai. 0000186364.27587.0e 16652057
38. Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8). Protopopescu C, Marcellin F, Spire B, Preau M, Verdon R, Peyramond D, Raffi F, Chene G, Leport C, Carrieri MP, Qual Life Res 2007 16 4 577 591 10.1007/s11136-006-9151-7 17268929 (Pubitemid 46474949)
39. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Caplehorn JR, Drummer OH, Med J Aust 1999 170 3 104 109 10065120 (Pubitemid 29060340)
40. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M, BMJ 2010 341 5475 10.1136/bmj.c5475 20978062
41. Changes to the daily pattern of methadone-related deaths in England and Wales, 1993-2003. Morgan OW, Johnson H, Rooney C, Seagroatt V, Griffiths C, J Public Health (Oxf) 2006 28 4 318 323 10.1093/pubmed/fdl059 (Pubitemid 44863320)
42. Creating a new drug service in Edinburgh. Greenwood J, BMJ 1990 300 6724 587 589 10.1136/bmj.300.6724.587 2108757 (Pubitemid 20090278)
43. Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists. Lawrinson P, Roche A, Terao H, Le PP, Drug Alcohol Rev 2008 27 1 47 53 10.1080/09595230701710852 18034381
44. Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995-2005. Sheridan J, Manning V, Ridge G, Mayet S, Strang J, Addiction 2007 102 11 1824 1830 10.1111/j.1360-0443.2007.02016.x 17935587 (Pubitemid 47573074)
45. Pharmacy syringe exchange program for injection drug users. Bonnet N, Presse Med 2006 35 12 Pt 1 1811 1818 17159732 (Pubitemid 44934574)